Share Prices & Company Research

Market News

21 Nov 2018 | 09:53

C4X Discovery trims annual losses as revenue swells

Drug company C4X Discovery said Wednesday annual losses before tax narrowed sharply as revenues swelled after it penned its first commercial deal during the year.

For the 12 months ended 31 July, losses before tax narrowed to £2.53m from £8.49m a year earlier and revenues swelled to £7.06m from £0.14m a year earlier.

The revenue uptick was driven by the amount received under the Indivior licensing agreement, the company said.

R&D expenses increased by 15% to £6.99M driven by the investment in both the increase in drug discovery activity and the continued development of lead drug candidates, the company added.

'The next year will focus on securing deal revenue from our next generation of discovery programmes, advancing our early stage pipeline towards commercialisation, and continuing to replenish and build our portfolio by identifying novel and exciting drug targets from Taxonomy 3 and beyond, C4X said.

At 9:53am: (LON:C4XD) C4x Discovery Holdings Plc share price was -2p at 84.5p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.